To elucidate the effect of cognitive functions on medication compliance of schizophrenia patients at stable phase, and provide clinical cognitive coping strategies to improve the medication compliance of schizophrenia patients.

Two hundred and thirty-eight schizophrenia patients at stable phase, admitted to psychiatry department of the 3^rd affiliated hospital of Sun Yat-sen University from May 2017 to October 2017, and all study subjects were divided into without medication compliance group (the scores of medication compliance scale≤4, n=32) and medication compliance group (the scores of medication compliance scale>4, n=206) by Medication Adherence Rating Scale (MARS). MATRICS Consensus Cognitive Battery (MCCB) and Brief Psychiatric Rating Scale (BPRS) were used to evaluate the differences of cognitive performance and disease severity between groups. The factors influencing medication compliance of schizophrenia patients with stable phase were explored by multiple linear regression analysis.

(1) The total scores of MCCB and it,s subscales scores (except for visual learning) of schizophrenia patients with medication compliance were higher than that of patients without medication compliance. The scores of symbol coding, spatial span and emotional intelligence ability in medication compliance group were significantly higher than those of patients without medication compliance (P<0.05). (2) Symbol coding (neurocognition ability), emotion management (social cognition ability), severity of illness, and antipsychotic drug dose were the independent influencing factors of medication compliance of schizophrenia patients with stable phase (P<0.05).

The medication compliance of schizophrenia patients with stable phase is not only affected by antipsychotics dose and severity of illness, but also affected by neurocognitive and social cognitive functions.

Schizophrenia; Neurocognition; Social cognition; Medication compliance